444 related articles for article (PubMed ID: 33614909)
1. Fascin actin-bundling protein 1 in human cancer: promising biomarker or therapeutic target?
Liu H; Zhang Y; Li L; Cao J; Guo Y; Wu Y; Gao W
Mol Ther Oncolytics; 2021 Mar; 20():240-264. PubMed ID: 33614909
[TBL] [Abstract][Full Text] [Related]
2. FSCN1 acts as a promising therapeutic target in the blockade of tumor cell motility: a review of its function, mechanism, and clinical significance.
Li Z; Shi J; Zhang N; Zheng X; Jin Y; Wen S; Hu W; Wu Y; Gao W
J Cancer; 2022; 13(8):2528-2539. PubMed ID: 35711849
[TBL] [Abstract][Full Text] [Related]
3. The crucial role of fascin-1 in the pathogenesis, metastasis, and chemotherapeutic resistance of breast cancer.
Abdullah AR; Gamal El-Din AM; El-Mahdy HA; Ismail Y; El-Husseiny AA
Pathol Res Pract; 2024 Feb; 254():155079. PubMed ID: 38219494
[TBL] [Abstract][Full Text] [Related]
4. Fascin in Gynecological Cancers: An Update of the Literature.
Gupta I; Vranic S; Al-Thawadi H; Al Moustafa AE
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830909
[TBL] [Abstract][Full Text] [Related]
5. The role and regulatory mechanism of FSCN1 in breast tumorigenesis and progression.
Chang D; Liu XX; Liu R; Sun JW
Yi Chuan; 2023 Feb; 45(2):115-127. PubMed ID: 36927659
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-133a inhibits proliferation and invasion, and induces apoptosis in gastric carcinoma cells via targeting fascin actin-bundling protein 1.
Lai C; Chen Z; Li R
Mol Med Rep; 2015 Jul; 12(1):1473-8. PubMed ID: 25815687
[TBL] [Abstract][Full Text] [Related]
7. Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer.
Cantini G; Fei L; Canu L; De Filpo G; Ercolino T; Nesi G; Mannelli M; Luconi M
Front Endocrinol (Lausanne); 2021; 12():698862. PubMed ID: 34248854
[TBL] [Abstract][Full Text] [Related]
8. Fascin actin-bundling protein 1 regulates non-small cell lung cancer progression by influencing the transcription and splicing of tumorigenesis-related genes.
Sun Q; Liu R; Zhang H; Zong L; Jing X; Ma L; Li J; Zhang L
PeerJ; 2023; 11():e16526. PubMed ID: 38077434
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Transcriptome and Pathway Analyses Revealed Central Role for Fascin in Promoting Triple-Negative Breast Cancer Progression.
Barnawi R; Al-Khaldi S; Majid S; Qattan A; Bakheet T; Fallatah M; Ghebeh H; Alajez NM; Al-Alwan M
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959629
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-145 inhibits migration and invasion via inhibition of fascin 1 protein expression in non-small-cell lung cancer cells.
Zhang Y; Yang X; Wu H; Zhou W; Liu Z
Mol Med Rep; 2015 Oct; 12(4):6193-8. PubMed ID: 26238532
[TBL] [Abstract][Full Text] [Related]
11. Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma.
Poli G; Ruggiero C; Cantini G; Canu L; Baroni G; Armignacco R; Jouinot A; Santi R; Ercolino T; Ragazzon B; Assie G; Mannelli M; Nesi G; Lalli E; Luconi M
J Clin Endocrinol Metab; 2019 May; 104(5):1712-1724. PubMed ID: 30476173
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of FSCN1 in non-small cell lung cancer.
Luo A; Yin Y; Li X; Xu H; Mei Q; Feng D
Biomed Pharmacother; 2015 Jul; 73():75-9. PubMed ID: 26211585
[TBL] [Abstract][Full Text] [Related]
13. Loss of MEG3 contributes to the enhanced migration and invasion in arsenic-induced carcinogenesis through NQO1/FSCN1 pathway.
Tu H; Zhang Z; Li J; Shi S; Costa M
Am J Cancer Res; 2023; 13(6):2307-2322. PubMed ID: 37424815
[TBL] [Abstract][Full Text] [Related]
14. ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression
Pu J; Zhang Y; Wang A; Qin Z; Zhuo C; Li W; Xu Z; Tang Q; Wang J; Wei H
Front Oncol; 2021; 11():754835. PubMed ID: 34733789
[TBL] [Abstract][Full Text] [Related]
15. Promoter Methylation-Regulated miR-145-5p Inhibits Laryngeal Squamous Cell Carcinoma Progression by Targeting FSCN1.
Gao W; Zhang C; Li W; Li H; Sang J; Zhao Q; Bo Y; Luo H; Zheng X; Lu Y; Shi Y; Yang D; Zhang R; Li Z; Cui J; Zhang Y; Niu M; Li J; Wu Z; Guo H; Xiang C; Wang J; Hou J; Zhang L; Thorne RF; Cui Y; Wu Y; Wen S; Wang B
Mol Ther; 2019 Feb; 27(2):365-379. PubMed ID: 30341010
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the Actin-Bundling Protein Fascin-1 Developed for Tumor Therapy Attenuate the T-Cell Stimulatory Properties of Dendritic Cells.
Zeyn Y; Harms G; Tubbe I; Montermann E; Röhrig N; Hartmann M; Grabbe S; Bros M
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681718
[TBL] [Abstract][Full Text] [Related]
17. Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study.
Tătaru OS; Martha O; Crocetto F; Barone B; Voidazan S; Borda A; Sin A; Hutanu A; Loghin A; Sin I; Porav-Hodade D; Chibelean CB; Vartolomei L; Lucarelli G; Ferro M; Osan VG; Buonerba C; Vartolomei MD
Future Sci OA; 2021 Oct; 7(9):FSO745. PubMed ID: 34737886
[TBL] [Abstract][Full Text] [Related]
18. SYTL2 promotes metastasis of prostate cancer cells by enhancing FSCN1-mediated pseudopodia formation and invasion.
Li Z; Tao Y; Gao Z; Peng S; Lai Y; Li K; Chen X; Huang H
J Transl Med; 2023 May; 21(1):303. PubMed ID: 37147713
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis reveals the potential biological function of FSCN1 in HeLa cervical cancer cells.
Guo F; Liu Y; Cheng Y; Zhang Q; Quan W; Wei Y; Hong L
PeerJ; 2022; 10():e12909. PubMed ID: 35178306
[TBL] [Abstract][Full Text] [Related]
20. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1.
Fuse M; Nohata N; Kojima S; Sakamoto S; Chiyomaru T; Kawakami K; Enokida H; Nakagawa M; Naya Y; Ichikawa T; Seki N
Int J Oncol; 2011 Apr; 38(4):1093-101. PubMed ID: 21258769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
